Sorafenib tosylate
别名: BAY 43-9006 tosylate,NSC-724772 tosylate
中文名称:甲苯磺酸索拉非尼
目录号:S1040 Purity: 99.99%
Sorafenib tosylate是Raf-1和B-Raf的多重激酶抑制剂,无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT,对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib Tosylate 可诱导autophagy、apoptosis并激活ferroptosis,并具有抗肿瘤活性。
CAS: 475207-59-1
客户使用Selleck的Sorafenib tosylate发表文献268篇
- Nature, 2024 629(8013):927-936
- Cell, 2023 S0092-8674(23)01032-2
- Cell, 2023 186(15):3208-3226.e27
- Cancer Cell, 2022 40(11):1306-1323.e8
- Cancer Cell, 2022 S1535-6108(21)00662-0
- Blood, 2022 blood.2021014304
- Cancer Cell, 2021 S1535-6108(21)00659-0
- Cell, 2020 182(3):685-712.e19
- Mol Cancer, 2020 19(1):139
- Nature, 2019 575(7781):203-209
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Gastroenterology, 2019 157(6):1615-1629
- Cell Metab, 2019 29(1):174-182
- Blood, 2013 122(9):1621-33
- Blood, 2012 120(19):4104-15
- Cell Mol Life Sci, 2024 81(1):238
- J Transl Med, 2024 22(1):593
- Front Immunol, 2024 15:1373321
- Cancer Sci, 2024 115(7):2220-2234
- PLoS One, 2024 19(5):e0299522
- bioRxiv, 2024 10.1101/2023.01.18.524628
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101286
- Sci Data, 2023 10(1):203
- Cell Death Dis, 2023 14(7):463
- Biomed Pharmacother, 2023 158:114176
- Free Radic Biol Med, 2023 202:110-120
- Cell Death Discov, 2023 9(1):92
- Cancers (Basel), 2023 15(18)4477
- Mol Cell Probes, 2023 67:101896
- Bioact Mater, 2022 18:459-470
- Cell Rep Med, 2022 3(1):100492
- J Exp Clin Cancer Res, 2022 41(1):249
- Proc Natl Acad Sci U S A, 2022 119(10):e2107453119
- Cancer Lett, 2022 548:215898
- Cancer Lett, 2022 543:215799
- Cell Death Dis, 2022 13(1):35
- Cell Death Dis, 2022 13(5):450
- Cell Death Dis, 2022 13(4):351
- Biomed Pharmacother, 2022 153:113363
- Biomed Pharmacother, 2022 153:113280
- J Transl Med, 2022 20(1):300
- Cell Oncol (Dordr), 2022 45(4):601-619
- Cancer Metab, 2022 10(1):4
- NPJ Breast Cancer, 2022 8(1):44
- Biochem Pharmacol, 2022 S0006-2952(22)00226-X
- Int J Mol Sci, 2022 23(8)4277
- Front Pharmacol, 2022 13:1032975
- Cancers (Basel), 2022 14(11)2733
- Transl Oncol, 2022 18:101362
- J Pers Med, 2022 12(2)258
- FASEB J, 2022 36(5):e22292
- Front Oncol, 2022 12:862326
- Biomedicines, 2022 10(2)321
- Toxicology, 2022 S0300-483X(22)00030-0
- Environ Toxicol, 2022 10.1002/tox.23680
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Toxicol Appl Pharmacol, 2022 447:116072
- J Trace Elem Med Biol, 2022 73:127043
- Oncol Lett, 2022 24(4):338
- Evid Based Complement Alternat Med, 2022 2022:6422500
- Commun Med (Lond), 2022 2:80
- Theranostics, 2021 11(12):5650-5674
- Redox Biol, 2021 46:102122
- Leukemia, 2021 10.1038/s41375-021-01308-z
- J Exp Clin Cancer Res, 2021 40(1):364
- J Colloid Interface Sci, 2021 608(Pt 1):239-254
- Int J Biol Sci, 2021 17(12):3133-3144
- Cell Death Dis, 2021 12(8):736
- Cell Death Dis, 2021 12(6):555
- Oncogene, 2021 10.1038/s41388-021-02130-8 10.1016/j.ccr.2014.01.005 10.1038/s41571-018-0105-0 10.1038/nature22071 10.1101/cshperspect.a031435 10.1007/s00595-012-0462
- Eur J Med Chem, 2021 223:113670
- Eur J Med Chem, 2021 226:113812
- Biomater Sci, 2021 10.1039/d0bm02107e
- Cell Biol Toxicol, 2021 10.1007/s10565-021-09607-y
- Front Cell Infect Microbiol, 2021 11:734750
- Int J Mol Sci, 2021 22(17)9151
- Front Pharmacol, 2021 12:615889
- Int J Mol Sci, 2021 22(9)4797
- Int J Mol Sci, 2021 22(10)5330
- Front Pharmacol, 2021 12:689767
- Front Cell Dev Biol, 2021 9:662868
- Front Cell Dev Biol, 2021 9:687524
- J Virol, 2021 JVI0119521
- Oncotarget, 2021 12(7):674-685
- Am J Cancer Res, 2021 11(6):2975-2989
- Cancers (Basel), 2021 13(14)3487
- Cancers (Basel), 2021 13(14)3635
- Aging (Albany NY), 2021 13(11):14999-15012
- Antibiotics (Basel), 2021 10(10)1223
- Carcinogenesis, 2021 bgab019
- Biomedicines, 2021 9(6)627
- Front Oncol, 2021 11:685694
- Front Oncol, 2021 11:796839
- Front Oncol, 2021 11:782065
- Front Oncol, 2021 11:648985
- Molecules, 2021 26(8)2141
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- PLoS Comput Biol, 2021 17(11):e1009515
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Membranes (Basel), 2021 11(8)636
- Onco Targets Ther, 2021 14:1049-1059
- J Clin Med, 2021 10(9)1889
- Endocr Relat Cancer, 2021 28(5):311-324
- Biochimie, 2021 184:8-17
- Toxicol Appl Pharmacol, 2021 414:115420
- PLoS One, 2021 16(7):e0253258
- Invest New Drugs, 2021 10.1007/s10637-021-01132-3
- DNA Cell Biol, 2021 40(11):1418-1427
- Biochem Biophys Res Commun, 2021 567:92-98
- Curr Oncol, 2021 28(3):2150-2172
- In Vivo, 2021 35(2):721-729
- Rapid Commun Mass Spectrom, 2021 e9130
- ProQuest, 2021 N/A
- Mol Cell, 2020 S1097-2765(20)30802-9
- Redox Biol, 2020 36:101652
- J Exp Clin Cancer Res, 2020 39(1):24
- J Control Release, 2020 322:602-609
- Adv Healthc Mater, 2020 10.1002/adhm.202001455
- Adv Healthc Mater, 2020 e2000650
- Cell Death Dis, 2020 11(10):822
- Cell Death Dis, 2020 11(3):178
- Elife, 2020 22;9:e51358
- Antiviral Res, 2020 178:104790
- J Transl Med, 2020 11;18(1):192
- J Genet Genomics, 2020 47(7):389-395
- Cancer Immunol Immunother, 2020 10.1007/s00262-020-02660-2
- Cancer Cell Int, 2020 19;20:58
- Biochem Pharmacol, 2020 182:114227
- J Cell Physiol, 2020 10.1002/jcp.29832
- J Mol Cell Biol, 2020 12(8):644-653
- Am J Cancer Res, 2020 10(10):3475-3486
- Cancers (Basel), 2020 12(11)E3172
- Cancers (Basel), 2020 27;12(5)pii: E1087
- Cancers (Basel), 2020 25;12(5)
- Cancers (Basel), 2020 13;12(2) pii: E436
- Cancers (Basel), 2020 12(7):E1972
- Front Oncol, 2020 10:878
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- BMC Cancer, 2020 20(1):936
- Toxicol In Vitro, 2020 71:105063
- Toxicol In Vitro, 2020 104928
- Basic Clin Pharmacol Toxicol, 2020 10.1111/bcpt.13525
- Mol Imaging Biol, 2020 10.1007/s11307-020-01531-7
- Biochem Biophys Res Commun, 2020 11;526(4):1170-1176
- Asian Pac J Cancer Prev, 2020 21(10):2853-2857
- J Pharmacol Toxicol Methods, 2020 106895
- Transl Cancer Res, 2020 9(3):1584-1593
- Methods Mol Biol, 2020 2138:175-183
- Mol Ther, 2019
- J Exp Clin Cancer Res, 2019 38(1):204
- Cancer Immunol Res, 2019 7(9):1523-1534
- Cancer Lett, 2019 454:14-25
- Hemasphere, 2019 3(2):e182
- Cancer, 2019 125(15):2693-2703
- Biochem Pharmacol, 2019 171:113682
- J Cell Physiol, 2019 234(4):4504-4514
- Am J Cancer Res, 2019 9(5):906-926
- J Cell Mol Med, 2019 23(9):6479-6493
- Front Oncol, 2019
- Sci Rep, 2019 9(1):18630
- Sci Rep, 2019 9(1):1897
- Food Chem Toxicol, 2019 126:303-312
- Exp Gerontol, 2019 126:110691
- Cancer Biol Ther, 2019
- Photodermatol Photoimmunol Photomed, 2019 10.1111/phpp.12520
- FEBS Open Bio, 2019 9(2):335-347
- Transl Cancer Res, 2019 8(4):1224-1232
- Nucleic Acids Res, 2018 46(4):2012-2029
- Clin Cancer Res, 2018 10.1158/1078-0432.CCR-18-0693
- Int J Biol Sci, 2018 14(13):1845-1858
- Antiviral Res, 2018 157:57-67
- J Lipid Res, 2018 59(11):2188-2201
- Lab Chip, 2018 18(15):2300-2312
- Int J Mol Sci, 2018 19(11)E3684
- Oncotarget, 2018
- Cancers (Basel), 2018 10(11)E455
- Lab Invest, 2018 98(6):734-744
- Sci Rep, 2018 8(1):948
- Pigment Cell Melanoma Res, 2018 31(2):253-266
- Food Chem Toxicol, 2018 119:464-478
- Gene, 2018
- Sci Transl Med, 2017 14;9(394):eaah6144
- Proc Natl Acad Sci U S A, 2017 114(11):2934-2939
- Cell Death Dis, 2017 8(6):e2904
- Br J Cancer, 2017 117(10):1518-1528
- Cell Rep, 2017
- Cell Chem Biol, 2017 24(7):858-869
- Int J Cancer, 2017 141(12):2571-2584
- Int J Pharm, 2017 528(1-2):485-497
- Mol Cancer Ther, 2017 16(6):1155-1165
- J Virol, 2017 91(21)e00968-17
- Oncotarget, 2017 8(38):63986-64000
- Oncotarget, 2017 8(25):41091-41101
- Oncotarget, 2017 8(28):45965-45980
- Oncotarget, 2017 8(8):13464-13475
- Oncotarget, 2017 8(7):11460-11479
- Oncotarget, 2017 8(52):90262-90277
- Oncotarget, 2017 8(14):23265-23276
- Oncotarget, 2017 8(42):71489-71499
- Methods, 2017 130:63-71
- Dig Liver Dis, 2017 49(2):213-222
- Proc Natl Acad Sci U S A, 2016 113(24):E3384-93
- Cancer Lett, 2016 377(2):149-57
- J Med Chem, 2016 59(3):925-33
- J Cell Physiol, 2016 231(10):2286-302
- Oncotarget, 2016 7(30):47018-47032
- Oncotarget, 2016 7(26):40398-40417
- Oncotarget, 2016 7(11):12975-96
- Oncotarget, 2016 7(17):23608-32
- Oncotarget, 2016 7(30):47465-47478
- Oncotarget, 2016 7(2):1826-37
- Mol Cell Biol, 2016 36(20):2612-25
- Sci Rep, 2016 6:28479
- Onco Targets Ther, 2016 9:6843-6855
- PLoS One, 2016 11(10):e0164752
- Cancer Biol Ther, 2016 17(11):1177-1187
- Leuk Res, 2016 45:68-74
- J Cell Physiol, 2015 230(1):131-9
- J Cell Physiol, 2015 230(10):2552-78
- Oncotarget, 2015 6(29):27227-38
- Oncotarget, 2015 6(15):13703-17
- Oncotarget, 2015 6(31):31927-43
- Front Microbiol, 2015 0.71944444444
- Mol Cell Endocrinol, 2015 404:37-45
- Exp Cell Res, 2015 331(1):97-104
- Cancer Biol Ther, 2015 16(11):1660-70
- Cell Death Dis, 2014 5:e1278
- Stem Cell Res Ther, 2014 5(2):37
- Anal Chem, 2014 86(21):10568-75
- Apoptosis, 2014 19(4):682-97
- Mol Oncol, 2014 8(7):1339-54
- Mol Cancer Res, 2014 12(10):1377-87
- J Cell Sci, 2014 127(Pt 7):1585-94
- PLoS One, 2014 9(6):e97739
- PLoS One, 2014 9(6):e100814
- Biomed Res Int, 2014 2014:764981
- Biochem Biophys Res Commun, 2014 450(1):19-24
- FEBS Open Bio, 2014 4:458-67
- Hepatology, 2013 59(4):1435-47
- Sci Signal, 2013 6(271):ra25
- Lab Invest, 2013 93(1):8-19
- Mol Cell Biochem, 2013 372(1-2):65-74
- Mol Cell Endocrinol, 2013 377(1-2):1-6
- Drug Metab Dispos, 2013 10.1124/dmd.113.054189
- PLoS One, 2013 8(12):e83521
- PLoS One, 2013 8(1):e54595
- PLoS One, 2013 8(6):e65726
- Planta Med, 2013 79(3-4):288-94
- Blood Cells Mol Dis, 2013 52(4):214-24
- J Biomol Screen, 2013 19(4):526-37
- Virginia Commonwealth University, 2013 2013
- Cell Death Differ, 2012 19(12):2029-39
- Haematologica, 2012 97(11):1722-30
- Br J Haematol, 2012 157(4):510-4
- Br J Haematol, 2012 157(4):483-92
- Int J Cancer, 2012 131(12):2961-9
- Int J Cancer, 2012 132(3):738-43
- Biochem Pharmacol, 2012 83(12):1674-81
- Mol Pharm, 2012 9(11):3062-78
- Surgery, 2012 152(6):1142-9
- Invest New Drugs, 2012 31(3):780-6
- Clin Cancer Res, 2011 17(24):7595-604
- J Invest Dermatol, 2011 131(9):1886-95
- Mol Pharmacol, 2011 80(6):1066-75
- Int J Parasitol, 2010 40(5):555-67
化学信息&溶解度
分子量 | 637.03 |
分子式 | C21H16ClF3N4O3.C7H8O3S |
CAS号 | 475207-59-1 |
Smiles | CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 127 mg/mL ( 199.36 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 0.01 mg/mL Ethanol : Insoluble DMSO : 100 mg/mL ( 156.97 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 33 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
95% Corn oil
浓度:4.9mg/ml
(7.69mM)
操作示例:以 1 mL 工作液为例,取50 μL 98 mg/ml的澄清 DMSO 储备液加到950 μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG 300
5%Tween80
50% ddH2O
浓度:4.9mg/ml
(7.69mM)
操作示例:以 1 mL 工作液为例,取 50 μL 98 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀使其澄清;向上述体系中加入50 μL Tween-80,混合均匀使其澄清;然后继续加入 500 μLddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。